Enzyme-mediated covalent binding of hydralazine to rat liver microsomes

Hydralazine was metabolized in vitro to a reactive metabolite(s) which bound to microsomal protein. The binding was dependent on mixed function oxidase activity, was proportional to time and microsomal protein concentration, and was not removed by acid washing. The apparent Km was 3.55 X 10(-5) M and the Vmax was 0.342 nmol/mg protein/min. Binding was inhibited by carbon monoxide and required oxygen and enzyme activity. Microsomes from animals pretreated with 3-methylcholanthrene showed a slight but significant increase in covalently bound hydralazine metabolite(s) whereas piperonyl butoxide treatment significantly reduced this binding. Glutathione, cysteine, and N-acetylcysteine all reduced the binding when added to incubations. Therefore, hydralazine is metabolized by the microsomal enzymes to a metabolite(s) capable of reacting covalently with cellular macromolecules.     

Studies on the formation of methoxychlor-protein adduct in rat and human liver microsomes. Is demethylation of methoxychlor essential for cytochrome P450 catalyzed covalent binding?

Previous studies demonstrated that liver microsomal monooxygenases metabolize the pesticide methoxychlor into phenolic estrogenic derivatives. Additionally, methoxychlor is activated by the hepatic cytochrome P450 monooxygenase to bind covalently to microsomal proteins (Bulger WH, Temple JE and Kupfer D, Toxicol Appl Pharmacol 68: 367-374, 1983). The current study examines, in liver microsomes from control and phenobarbital-treated rats and humans, whether demethylation of methoxychlor is essential for covalent binding and whether demethylated methoxychlor metabolites are on the pathway of formation of the reactive intermediate and protein adduct. Using 3H-methoxyl-labeled and 14C-ring-labeled methoxychlor, it was demonstrated that demethylation is not essential for covalent binding. Namely, the major portion of the methoxychlor moiety in the protein adduct was found to contain intact methoxyls. Nevertheless, in the absence of methoxychlor, both the mono- and bis-demethylated methoxychlor metabolites could undergo monooxygenase-mediated covalent binding to proteins. This was demonstrated in incubations of purified 14C-labeled mono- and bis-demethylated methoxychlor metabolites with liver microsomes, in the presence of NADPH. Additionally, the dehydrochlorinated metabolite of methoxychlor, containing a double bond, underwent covalent binding, which exhibited characteristics similar to those of methoxychlor. These findings demonstrated that the protein adduct from relatively brief incubation periods contains a methoxychlor derivative with intact methoxyls. The possibility that the activation of methoxychlor involves modification of the side chain, which is the active site that binds to proteins, is discussed.     

Metabolic activation of 1-naphthol by rat liver microsomes to 1,4-naphthoquinone and covalent binding species

1-Naphthol was metabolized by rat liver microsomes, in the presence of an NADPH-generating system, both to methanol-soluble metabolites including 1,4-naphthoquinone and an uncharacterized product(s) (X) and also to covalently bound products. NADH was much less effective as an electron donor than NADPH. Metyrapone, SKF 525-A and carbon monoxide all inhibited the metabolism of 1-naphthol to 1,4-naphthoquinone and to covalently bound products suggesting the involvement of cytochrome P-450 in at least one step in the metabolic activation of 1-naphthol to reactive products. Ethylene diamine, which reacts selectively with 1,2-naphthoquinone but not 1,4-naphthoquinone, did not affect the covalent binding whereas glutathione, which reacts with both naphthoquinones, caused an almost total inhibition of covalent binding. These and other results suggested that 1,4-naphthoquinone, or a metabolite derived from it, was responsible for most of the covalent binding observed and that little if any of the binding was due to 1,2-naphthoquinone.     

In vitro covalent binding of the pyrethroids cismethrin,cypermethrin and deltamethrin to rat liver homogenate and microsomes

Phenobarbital-induced rat liver homogenate and microsomes were used to study covalent binding of l4C-labelled (at the alcohol moiety) cismethrin, ¹⁴C-labelled (at the alcohol and acid moieties) cypermethrin, and ¹⁴C-labelled (at the alcohol and acid moieties) deltamethrin. Covalent binding was dependent on pyrethroid concentration. With liver homogenate, inhibition of esterases by tetraethylpyrophosphate and of mitochondrial respiration by rotenone or potassium cyanide only slightly altered the covalent binding level. With microsomes, inhibition of cytochrome P-450 and mixed function oxidases by carbon monoxide and piperonyl butoxide reduced the covalent binding so far as to be nearly absent. Eighty percent inhibition of epoxide hydrolase decreased the covalent binding by 50%. The comparison of data between alcohol and acid labelling of the same pyrethroid suggested that, in vitro, the whole molecule is bound to proteins and that hydrolysis can occur afterwards. The experiments stress the role of cytochrome P-450-dependent monoxygenases in the covalent binding process.     

Characteristics of the active oxygen in covalent binding of the pesticide methoxychlor to hepatic microsomal proteins

This study examined the characteristics of the active oxygen species involved in generation of the reactive intermediate of methoxychlor which covalently binds to liver microsomal proteins. The possibility that the active oxygen participating in the above reaction is the superoxide anion (O2-) or a species generated from O2- was examined with the help of superoxide dismutase (SOD) and with an SOD-mimetic agent, CuDIPS [Cu2+(3,5-diisopropylsalicylic acid)2]. It was observed that, whereas CuDIPS inhibited covalent binding of methoxychlor metabolite(s), SOD did not. However, ZnDIPS [Zn2+(3,5-diisopropylsalicylic acid)2], which exhibits no SOD-mimetic activity, did not inhibit covalent binding. Furthermore, both CuDIPS and ZnDIPS had little or no effect on the formation of demethylated (polar) metabolites of methoxychlor, demonstrating that the inhibition of covalent binding by CuDIPS was not merely due to a general inhibition of the hepatic monooxygenase system. These findings suggested that O2- was involved in covalent binding, but was not accessible to SOD. Additional support for O2- involvement stems from the observation that alpha-tocopheryl acid succinate markedly inhibited covalent binding of methoxychlor. The possibility that hydrogen peroxide (H2O2) was involved in covalent binding of methoxychlor appears unlikely. Catalase had no effect on covalent binding when NADPH was the cofactor, and the use of H2O2 in place of NADPH did not yield covalent binding. Certain scavengers of hydroxyl radical (ethanol, t-butanol and benzoate) inhibited, and other known scavengers (DMSO and mannitol) did not inhibit, covalent binding. EDTA stimulated binding, desferal (desferrioxamine) exhibited no effect on binding, and diethylenetriaminepentaacetic acid (DETAPAC) inhibited binding. A possible explanation for this observation is that the Fe2+ needed for generation of X OH is much more easily obtained from Fe3+-EDTA than from Fe3+-desferal, which resists reduction. The inhibitory effect by DETAPAC may be due to chelation of another metal which is needed for the reaction. Lastly, certain scavengers of singlet oxygen inhibited covalent binding with little effect on the formation of polar metabolites of methoxychlor. In conclusion, these studies support the involvement of X OH and singlet oxygen, possibly derived from O2-, in the formation of the reactive methoxychlor intermediate.(ABSTRACT TRUNCATED AT 400 WORDS)     

Flavin-containing monooxygenase-mediated metabolism of N-deacetyl ketoconazole by rat hepatic microsomes.

Although ketoconazole is extensively metabolized by hepatic microsomal enzymes, the route of formation and toxicity of suspected metabolites are largely unknown. Reports indicate that N-deacetyl ketoconazole (DAK) is a major initial metabolite in mice. DAK may be susceptible to successive oxidative attacks on the N-1 position by flavin-containing monooxygenases (FMO) producing potentially toxic metabolites. Previous laboratory findings have demonstrated that postnatal rat hepatic microsomes metabolize DAK by NADPH-dependent monooxygenases to two metabolites as determined by HPLC. Our current investigation evaluated DAK's metabolism in adult male and female rats and identified metabolites that may be responsible for ketoconazole's hepatotoxicity. DAK was extensively metabolized by rat liver microsomal monooxygenases at pH 8.8 in pyrophosphate buffer containing the glucose 6-phosphate NADPH-generating system to three metabolites as determined by HPLC. The initial metabolite of DAK was a secondary hydroxylamine, N-deacetyl-N-hydroxyketoconazole, which was confirmed by liquid chromatography/mass spectrometry and NMR spectroscopy. Extensive metabolism of DAK occurred at pH 8.8 in pyrophosphate buffer (female 29% and male 53% at 0.25 h; female 55% and male 57% at 0.5 h; and female 62% and male 66% at 1.0 h). Significantly less metabolism of DAK occurred at pH 7.4 in phosphate buffer (female 11%, male 17% at 0.25 h; female 20%, male 31% at 0.5 h; and female 27%, male 37% at 1 h). Heat inactivation of microsomal-FMO abolished the formation of these metabolites from DAK. SKF-525A did not inhibit this reaction. These results suggest that DAK appears to be extensively metabolized by adult FMO-mediated monooxygenation.     

In vitro covalent binding of new brain tracer, para-125I-amphetamine, to rat liver and lung microsomes

p-125I-amphetamine (I-Amp) is retained significantly in liver and lung during brain tomoscintigraphy. To attempt to explain this clinical observation, we have investigated the interaction of I-Amp with rat liver and lung microsomal proteins. Studies using spectral shift technique indicate that low concentration of I-Amp gives a type I complex and high concentration appears very stable type II complex with cytochrome P-450 Fe III. In the presence of NADPH, I-Amp gives rise to a 455 nm absorbing complex with similar properties to the Fe-RNO complexes. This complex formation was greatly enhanced with phenobarbital treated liver microsomes. The in vitro binding study shows that I-Amp and/or its metabolites was covalently bound to macromolecules in the presence of the molecular oxygen and NADPH-generating system. Incubation in the presence of glutathione, cystein and radical scavengers decreases binding. Mixed function oxydase (MFO) inhibitors diminish the amount of covalent binding and alter the extent of metabolite formation. The total covalent binding level increased with liver microsomes from PB pretreated rats as it was observed with the 455nm complex formation. The radioactivity distribution on microsomal proteins was examinated with SDS polyacrylamide gel electrophoresis and autoradiography. This experiment proves that the radiolabelled compounds are bound on the cytochrome P-450. The radioactivity bound increased when the PB induced rat liver microsomes were used. All these results indicate that I-Amp was activated by an oxydative process dependent on the MFO system which suggests a N-oxydation of I-Amp and the formation of reactive entities which covalently bind to proteins.     

Nonspecific binding of drugs to human liver microsomes

AIMS: To characterize the nonspecific binding to human liver microsomes of drugs with varying physicochemical characteristics, and to develop a model for the effect of nonspecific binding on the in vitro kinetics of drug metabolism enzymes. METHODS: The extent of nonspecific binding to human liver microsomes of the acidic drugs caffeine, naproxen, tolbutamide and phenytoin, and of the basic drugs amiodarone, amitriptyline and nortriptyline was investigated. These drugs were chosen for study on the basis of their lipophilicity, charge, and extent of ionization at pH 7.4. The fraction of drug unbound in the microsomal mixture, fu(mic), was determined by equilibrium dialysis against 0.1 M phosphate buffer, pH 7.4. The data were fitted to a standard saturable binding model defined by the binding affinity KD, and the maximum binding capacity Bmax. The derived binding parameters, KD and Bmax, were used to simulate the effects of saturable nonspecific binding on in vitro enzyme kinetics. RESULTS: The acidic drugs caffeine, tolbutamide and naproxen did not bind appreciably to the microsomal membrane. Phenytoin, a lipophilic weak acid which is mainly unionized at pH 7. 4, was bound to a small extent (fu(mic) = 0.88) and the binding did not depend on drug concentration over the range used. The three weak bases amiodarone, amitriptyline and nortriptyline all bound extensively to the microsomal membrane. The binding was saturable for nortriptyline and amitriptyline. Bmax and KD values for nortriptyline at 1 mg ml-1 microsomal protein were 382 +/- 54 microM and 147 +/- 44 microM, respectively, and for amitriptyline were 375 +/- 23 microM and 178 +/- 33 microM, respectively. Bmax, but not KD, varied approximately proportionately with the microsome concentration. When KD is much less than the Km for a reaction, the apparent Km based on total drug can be corrected by multiplying by fu(mic). When the substrate concentration used in a kinetic study is similar to or greater than the KD (Km >/= KD), simulations predict complex effects on the reaction kinetics. When expressed in terms of total drug concentrations, sigmoidal reaction velocity vs substrate concentration plots and curved Eadie Hofstee plots are predicted. CONCLUSIONS: Nonspecific drug binding in microsomal incubation mixtures can be qualitatively predicted from the physicochemical characteristics of the drug substrate. The binding of lipophilic weak bases is saturable and can be described by a standard binding model. If the substrate concentrations used for in vitro kinetic studies are in the saturable binding range, complex effects are predicted on the reaction kinetics when expressed in terms of total (added) drug concentration. Sigmoidal reaction curves result which are similar to the Hill plots seen with cooperative substrate binding.     

In vivo covalent binding of clofibric acid to human plasma proteins and rat liver proteins

Recent studies have shown that acyl-glucuronide conjugates are chemically reactive electrophilic metabolites that can undergo transacylation reactions resulting in intra-molecular rearrangement, hydrolysis and covalent binding of aglycone to albumin both in vitro and in vivo. The hypolipidaemic agent clofibrate is eliminated almost entirely as clofibric acid glucuronide in humans and rats. The formation of clofibric acid-protein adducts was investigated in 14 patients receiving 0.5-2.0 g/day of clofibrate for hypercholesterolaemia, and in liver homogenates from 20 rats administered 280 mg/kg/day of clofibric acid for up to 21 days. Total clofibric acid concentrations in the patients ranged from 0 to 114 mg/L. Covalently bound clofibric acid-protein adducts were detected in all patients, even in one subject in whom there was no measurable plasma clofibric acid. Concentrations ranged from 2.2 to 53.4 ng/mg protein and, in eight patients receiving 1.0 g/day of clofibrate, were correlated (P less than 0.05) with renal function as assessed by creatinine clearance. Clofibric acid-protein adducts were also present in rat liver homogenates, and increased with increasing duration of treatment (P less than 0.0001), from a mean (SE) of 10.1 (0.7) to 32.3 (1.6) ng/mg protein. The covalent binding of drugs to tissue macromolecules has traditionally been associated with toxicity. Further research is required to elucidate the role of acyl-glucuronide conjugates in the formation of drug-protein adducts and their biological consequences.     

Covalent binding of trans-stilbene to rat liver microsomes.

A number of estrogenic compounds have been shown to bind covalently to tissue macromolecules. Some of these agents cause impairement of liver function as measured by bromosulfophthalein clearance time. Trans-stilbene, a weak synthetic estrogen, which has been shown to be hydroxylated in several animal species, was investigated to determine if it covalently binds to tissue macromolecules. Liver damage was also evaluated histopathologically. Trans-stilbene binds covalently in vivo to various tissues of non-pretreated, phenobarbital-pretreated and 3-methylcholanthrene-pretreated rats. Pretreatment with 3-methylcholanthrene caused the greatest amounts of ¹⁴C-trans-stilbene to covalently bind to plasma and liver proteins. Studies in vitro showed that ¹⁴C-trans-stilbene became covalently bound to hepatic microsomes and that the covalent binding of ¹⁴C-trans-stilbene to liver microsomes from non-pretreated, phenobarbital-pretreated and 3-methylcholanthrene-pretreated rats was linear with time for at least 20 min. Oxygen and NADPH were necessary for binding. Carbon monoxide inhibited covalent binding to microsomes from non-pretreated rats and, to a much lesser extent, to microsomes from 3-methylcholanthrene-pretreated rats. The effects of various pretreatments on the covalent binding in vitro paralleled those of the binding in vivo. Although trans-stilbene was seen to bind covalently in vivo and in vitro, no histopathological abnormalities of liver or kidney were observed. Pretreatment of rats with phenobarbital or 3-methylcholanthrene, before administration of trans-stilbene, also did not cause any tissue abnormalities in liver or kidney. Glutathione did not seem to act as a protective agent in this study because, even after complete depletion of this substance, trans-stilbene did not cause any significant liver or kidney histopathological changes.     

Lindane metabolism by human and rat liver microsomes

1. Human liver microsomes convert lindane (gamma isomer of 1,2,3,4,5,6-hexachlorocyclohexane) to four major primary metabolites; gamma-1,2,3,4,5,6-hexachlorocyclohex-1-ene (3,6/4,5-HCCH), gamma-1,3,4,5,6-pentachlorocyclohex-1-ene (3,6/4,5-PCCH), beta-1,3,4,5,6-pentachlorocyclohex-1-ene (3,4,6/5-PCCH), and 2,4,6-trichlorophenol (2,4,6-TCP); and two major secondary metabolites; 2,3,4,6-tetrachlorophenol (2,3,4,6-TTCP) and pentachlorobenzene (PCB). 2. Under the same conditions, rat liver microsomes produce 3,6/4,5-HCCH, 2,4,6-TCP and 2,3,4,6-TCCP at rates similar to human liver microsomes. 3,4,6/5-PCCH is produced at much lower rates and 3,6/4,5-PCCH and PCB are not detected when lindane is incubated with rat liver microsomes for up to 30 min. 3. The identity of 3,4,6/5-PCCH, previously not identified as a mammalian metabolite of lindane, is confirmed by column chromatography and g.l.c.-mass spectrometry by comparison with authentic material. 4. It is concluded that there is potentially substantial hepatic metabolism by humans of lindane, a topically used scabicide and pediculicide.     

In vitro covalent binding of nafenopin-CoA to human liver proteins

Endogenous fatty acyl-CoAs play an important role in the acylation of proteins. A number of xenobiotic carboxylic acids are able to mimic fatty acids, forming CoA conjugates and acting as substrates in pathways of lipid metabolism. In this study nafenopin, a substrate for human hepatic fatty acid-CoA ligases, was chosen as a model compound to study xenobiotic acylation of human liver proteins. (3)H-nafenopin (+/- unlabeled palmitate) or (14)C-palmitate (+/- unlabeled nafenopin) were incubated for up to 120 min at 37 degrees C with ATP, CoA, and homogenate protein (1 mg/ml) from four individual human livers. Nafenopin covalently bound to proteins was detectable in all human livers and increased with time. Nafenopin adduct formation was directly proportional to nafenopin-CoA formation (r = 0.985, p < 0.05). Attachment of nafenopin to proteins involved both thioester and amide linkages with 76 and 24% of adducts formed with proteins > 100 and 50-100 kDa, respectively. Protein acylation by palmitate was also demonstrated. Palmitate significantly inhibited nafenopin-CoA formation by 29% but had no effect on nafenopin-CoA-mediated protein acylation. In contrast, nafenopin significantly inhibited protein palmitoylation by palmitoyl-CoA. This is the first study to demonstrate a direct relationship between xenobiotic-CoA formation, acylation of human liver proteins, and inhibition of endogenous palmitoylation. The ability of xenobiotics to acylate tissue proteins may have important biological consequences including perturbation of endogenous regulation of protein localization and function.     

Irreversible protein binding of [14-C]imipramine with rat and human liver microsomes.

After incubation of [¹⁴C]imipramine with rat liver microsomcs up to 0–7 mole/mg was irreversibly bound per mg of microsomal protein. If albumin was added to the microsomal incubations [¹⁴C]imiprámine was also irreversibly bound to this protein. The irreversible binding of imipramine to protein was determined by exhaustive solvent extraction and charcoal adsorption, and measurement of the remaining ¹⁴C-radioactivity in the protein. The binding reaction was dependent on oxygen, NADPH, microsomal protein content and substrate concentration. It was inhibited by CO and SKF 525-A. Pretreatment of rats with phenobarbital did not increase the amount of imipramine irreversibly bound to protein. Glutathione and other cysteine derivatives diminished the binding, whereas incubation with the epoxide hydrase inhibitor trichloropropene oxide resulted in an increase of imipramine irreversibly bound to protein. The results favour the concept that irreversible protein binding of imipramine is catalyzed by a cytochrome P-450-dependent hydroxylation via an epoxidation step. Irreversible protein binding of imipramine was also detectable with three samples of human liver microsomes.     

Metabolism and covalent binding of [14C]toluene by human and rat liver microsomal fractions and liver slices

The in vitro metabolism of [14C]toluene by liver microsomes and liver slices from male Fischer F344 rats and human subjects has been compared. Rat liver microsomes produced only benzyl alcohol from toluene. Liver microsomes from human subjects metabolized toluene to benzyl alcohol, benzaldehyde, and benzoic acid. Liver microsomes from one human donor also produced p-cresol and o-cresol. The overall rate of toluene metabolism by human liver microsomes was 9-fold greater than by rat liver microsomes. Human liver microsomal metabolism of benzyl alcohol to benzaldehyde required NADPH and was inhibited by carbon monoxide and high pH (pH 10). but was not inhibited by ADP-ribose or sodium azide. These results suggest that cytochrome P-450, rather than alcohol dehydrogenase, was responsible for the metabolism of benzyl alcohol to benzaldehyde. Human and rat liver slices metabolized toluene to hippuric acid and benzoic acid. The overall rate of toluene metabolism by human liver slices was 1.3-fold greater than by rat liver slices. Cresols and cresol conjugates were not detected in human or rat liver slice incubations. Covalent binding of [14C]toluene to human liver microsomes and slices was 21-fold and 4-fold greater than to the comparable rat liver preparations. Covalent binding did not occur in the absence of NADPH, was significantly decreased by coincubation with cysteine, glutathione, or superoxide dismutase, and was unaffected by coincubation with lysine. Protease and ribonuclease digestion decreased the amount of toluene covalently bound to human liver microsomes by 78% and 27% respectively. Acid washing of human liver microsomes had no effect on covalent binding.(ABSTRACT TRUNCATED AT 250 WORDS)     

Evidence for covalent binding of adriamycin to rat liver microsomal proteins

Adriamycin (NSC-123, 127) is an anticancer drug of the anthracycline type widely used in the clinical practice for the treatment of different malignancies (1). Intercalation with DNA has been suggested as having a role in the mechanism of action of this drug (2, 3, 4). Recently, reports by Sinha (5) and Lucacchini et al. (6) suggested a covalent interaction of Adriamycin (AM) with DNA and proteins. These studies, however, were not conclusive since they were carried out by spectrophotometric and Chromatographie procedures. In the present study a covalent interaction between AM and microsomal proteins was demonstrated in a more “classical” covalent binding study with the ¹⁴C-labelled compound.     

Metabolism of lovastatin by rat and human liver microsomes in vitro

The metabolism of lovastatin (Mevacor) was examined using isolated microsomes derived from the livers of normal and phenobarbital-treated rats and from human liver samples. Incubation of lovastatin with rat liver microsomes resulted in the formation of several polar metabolites of lovastatin. The metabolites were isolated by HPLC and identified by NMR and mass spectrometry. One fraction consisted of a 2:1 mixture of 6-hydroxy-lovastatin and the rearrangement product delta 4,5-3-hydroxy lovastatin. Addition of a trace of acid to this mixture resulted in the formation of a single aromatized product, the desacyl-delta 4a,6,8-dehydro analog of lovastatin. Another microsomal metabolite was determined to be the delta 4,8a,1-3-hydroxy-lovastatin derivative. The chromatographic pattern of metabolites produced from lovastatin by human liver microsomes was similar to that obtained with rat liver microsomes. Metabolism of lovastatin by rat liver microsomes was both time and concentration dependent; optimal microsomal metabolism occurred with 0.1 mM lovastatin, whereas higher lovastatin concentrations inhibited the reaction. The open acid form of lovastatin was poorly metabolized by both the rat and the human liver microsomes.     

Characteristics of warfarin hydroxylation catalyzed by human liver microsomes

The oxidative biotransformation of (R)- and (S)-warfarin was studied in human liver microsomes to determine whether an in vitro model could be established that would correspond to the in vivo profile that is generally observed. The quantitative pattern of oxidized products obtained from warfarin in vitro changed dramatically as a function of substrate concentration. Apparent Km values for the formation of 4', 6, 7, and 8-hydroxywarfarin indicated the presence of two easily distinguishable subsets of human liver cytochrome P-450; a high affinity subset (Km 3-15 microM) and a low affinity subset of isozymes (Km greater than 200 microM). The high affinity subset is primarily responsible for the metabolic profile of the biologically more potent (S)-enantiomer in vivo, whereas the low affinity subset is largely responsible for metabolism of the (R)-enantiomer. Apparent Vmax values alone did not reflect the relative in vivo formation clearances of the phenolic metabolites from either antipode, because the low affinity-high capacity component masked the metabolic profile of the (S)-enantiomer. However, the rank order of intrinsic clearance, Vmax/Km, for each metabolite was in good agreement with regio- and stereoselective metabolism in vivo. This investigation highlights the need for rigorous kinetic characterization of an in vitro model before reasonable correlation can be expected with in vivo data.     

补骨脂素和异补骨脂素在大鼠和人肝微粒体的酶促动力学

目的研究中药有效成分补骨脂素和异补骨脂素的细胞色素P450(CYP)酶促动力学特征,比较其结构和种属差异,为体内药代动力学特征的预测提供科学依据。方法建立补骨脂素和异补骨脂素的液相色谱串联质谱(LC-MS/MS)检测方法,在优化人和大鼠肝微粒体孵育体系和评价体外代谢稳定性的基础上,进行了代谢稳定性和酶促动力学研究,应用非线性回归法计算最大反应速率(V_(max))和米氏常数(K_m)。结果应用建立的LC-MS/MS检测方法,补骨脂素、异补骨脂素在肝微粒体孵育液中定量范围为0.1~50.0μmol·L~(-1),线性关系良好,精密度和准确度等满足检测要求。体外代谢稳定性研究显示,当底物浓度为1μmol·L~(-1),蛋白浓度为0.5 g·L~(-1),孵育40 min内,补骨脂素和异补骨脂素在大鼠和人肝微粒体呈线性消除,体外半衰期分别为74.5,95.0,74.5和173.3 min。补骨脂素在大鼠和人肝微粒体中的V_(max)分别为:(1.140±0.080)μmol·min-1·g-1蛋白,(0.620±0.060)μmol·min-1·g-1蛋白;K_m分别为(12.9±0.3)μmol·L~(-1)和(7.4±1.3)μmol·L~(-1)。异补骨脂素在大鼠和人肝微粒体中的V_(max)分别为(0.251±0.012)μmol·min-1·g-1蛋白和(0.103±0.014)μmol·min-1·g-1蛋白;K_m分别为:(3.0±0.4)μmol·L~(-1)和(3.4±0.7)μmol·L~(-1)。结论补骨脂素和异补骨脂素的CYP酶促动力学特征及代谢稳定性具有一定的种属和结构差异,在大鼠两者基于CYP酶的代谢清除过程可能相似。而在人体,异补骨脂素的CYP代谢清除可能慢于补骨脂素,导致药代动力学特征的差异。